Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.19% $0.696
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 25.34 mill |
EPS: | -1.000 |
P/E: | -0.700 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 36.39 mill |
Avg Daily Volume: | 0.0352 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.700 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.12x |
Company: PE -0.700 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.379 (-45.58%) $-0.317 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 0.643 - 0.749 ( +/- 7.61%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Finck Barbara K | Buy | 175 000 | Stock Option (right to buy) |
2024-03-21 | Riley Antony A | Buy | 350 000 | Stock Option (right to buy) |
2024-03-21 | Wagner Paul A. | Buy | 1 100 000 | Stock Option (right to buy) |
2024-01-01 | Chen Hubert C | Buy | 7 500 | Common Stock |
2024-01-01 | Chen Hubert C | Sell | 3 073 | Common Stock |
INSIDER POWER |
---|
89.26 |
Last 93 transactions |
Buy: 4 737 754 | Sell: 316 977 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.696 (0.19% ) |
Volume | 0.0522 mill |
Avg. Vol. | 0.0352 mill |
% of Avg. Vol | 148.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.